KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial - Trial NCT06370026
Access comprehensive clinical trial information for NCT06370026 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 1
May 01, 2024
Dec 31, 2026
Primary Outcome
The incidence Adverse events (Safety endpoint)
Summary
The main purpse of this study is to evaluate the safety of KSD-101 in patients with
 EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and
 evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated
 Nasopharyngeal Carcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370026
Non-Device Trial